X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6259) 6259
Book Chapter (101) 101
Conference Proceeding (4) 4
Web Resource (4) 4
Magazine Article (3) 3
Dissertation (1) 1
Newsletter (1) 1
Publication (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (5775) 5775
humans (5201) 5201
science & technology (5013) 5013
life sciences & biomedicine (4897) 4897
female (3245) 3245
male (2708) 2708
oncology (2566) 2566
middle aged (2520) 2520
aged (2377) 2377
antibodies, monoclonal, humanized (1768) 1768
adult (1765) 1765
angiogenesis inhibitors - therapeutic use (1591) 1591
treatment outcome (1563) 1563
antineoplastic combined chemotherapy protocols - therapeutic use (1509) 1509
ophthalmology (1426) 1426
angiogenesis inhibitors - adverse effects (1413) 1413
vascular endothelial growth factor a - antagonists & inhibitors (1383) 1383
vascular endothelial growth factor (1296) 1296
chemotherapy (1260) 1260
cancer (1247) 1247
angiogenesis inhibitors - administration & dosage (1182) 1182
aged, 80 and over (1075) 1075
care and treatment (1038) 1038
antineoplastic combined chemotherapy protocols - adverse effects (1009) 1009
antibodies, monoclonal - adverse effects (1004) 1004
antibodies, monoclonal, humanized - administration & dosage (995) 995
antibodies, monoclonal - administration & dosage (927) 927
antibodies, monoclonal - therapeutic use (906) 906
antibodies, monoclonal, humanized - adverse effects (885) 885
retrospective studies (838) 838
angiogenesis inhibitors (814) 814
medicine & public health (811) 811
antibodies, monoclonal, humanized - therapeutic use (794) 794
colorectal neoplasms - drug therapy (785) 785
colorectal cancer (772) 772
metastasis (735) 735
disease-free survival (734) 734
intravitreal injections (720) 720
bevacizumab - administration & dosage (694) 694
drug therapy (679) 679
research (650) 650
clinical trials (621) 621
angiogenesis (604) 604
pharmacology & pharmacy (595) 595
follow-up studies (584) 584
patients (583) 583
ranibizumab (551) 551
colorectal neoplasms - pathology (539) 539
bevacizumab - adverse effects (531) 531
antineoplastic agents (528) 528
bevacizumab - therapeutic use (515) 515
antimitotic agents (506) 506
antineoplastic agents - therapeutic use (494) 494
antineoplastic combined chemotherapy protocols - administration & dosage (488) 488
fluorouracil - administration & dosage (480) 480
hematology, oncology and palliative medicine (479) 479
tomography, optical coherence (462) 462
surgery (457) 457
eye diseases (452) 452
animals (444) 444
cancer therapies (442) 442
analysis (440) 440
prospective studies (435) 435
macular degeneration (432) 432
lung neoplasms - drug therapy (431) 431
neoplasm metastasis (430) 430
health aspects (400) 400
risk factors (396) 396
neoplasm staging (394) 394
camptothecin - analogs & derivatives (388) 388
genetic structures (384) 384
abridged index medicus (379) 379
breast neoplasms - drug therapy (379) 379
prognosis (376) 376
fluorescein angiography (361) 361
tumors (359) 359
visual acuity (359) 359
studies (354) 354
young adult (354) 354
carcinoma, non-small-cell lung - drug therapy (346) 346
vitreous body (346) 346
monoclonal antibodies (345) 345
breast cancer (342) 342
antineoplastic agents - adverse effects (340) 340
injections (337) 337
organoplatinum compounds - administration & dosage (337) 337
vegf (334) 334
macular degeneration - drug therapy (333) 333
survival (324) 324
macular edema - drug therapy (319) 319
visual acuity - physiology (316) 316
drug administration schedule (314) 314
deoxycytidine - analogs & derivatives (311) 311
choroidal neovascularization - drug therapy (309) 309
survival rate (302) 302
combined modality therapy (301) 301
brain neoplasms - drug therapy (296) 296
camptothecin - administration & dosage (291) 291
randomized controlled trials as topic (290) 290
hypertension (289) 289
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6115) 6115
Japanese (112) 112
French (80) 80
German (73) 73
Spanish (29) 29
Chinese (22) 22
Korean (15) 15
Italian (8) 8
Polish (8) 8
Russian (8) 8
Portuguese (7) 7
Czech (5) 5
Hungarian (3) 3
Norwegian (2) 2
Danish (1) 1
Dutch (1) 1
Indonesian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents | Index Medicus
Journal Article
Journal Article
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2012, Volume 39, Issue 4, pp. 388 - 401
Abstract Background To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management... 
Hematology, Oncology and Palliative Medicine | Side effects | Adverse events | Targeted therapy | Renal cell carcinoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Humans | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Protein Kinase Inhibitors - adverse effects | Bevacizumab | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Molecular Targeted Therapy - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Imidazoles - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Care and treatment | Metastasis | Carcinoma, Renal cell | Cancer | Index Medicus
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 07/2009, Volume 6, Issue 8, pp. 465 - 477
.... with expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Benzenesulfonates - adverse effects | Bevacizumab | Brain Diseases - chemically induced | Benzenesulfonates - pharmacology | Pyridines - adverse effects | Drug Interactions | Kidney Diseases - chemically induced | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal - pharmacology | Risk Factors | Angiogenesis Inhibitors - pharmacology | Forecasting | Indoles - adverse effects | Indoles - therapeutic use | Cardiovascular Diseases - chemically induced | Hemorrhage - chemically induced | Vascular Endothelial Growth Factor A - physiology | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor - physiology | Clinical Trials as Topic - statistics & numerical data | Neoplasm Proteins - physiology | Antibodies, Monoclonal - adverse effects | Cardiovascular Diseases - therapy | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Pyrroles - therapeutic use | Wound Healing - drug effects | Pyridines - therapeutic use | Hemorrhage - therapy | Pyrroles - pharmacology | Protein Kinase Inhibitors - therapeutic use | Capillary Leak Syndrome - chemically induced | Kidney Diseases - therapy | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Gastrointestinal Diseases - chemically induced | Antimitotic agents | Complications and side effects | Care and treatment | Colorectal cancer | Physiological aspects | Development and progression | Poisoning | Antineoplastic agents | Vascular endothelial growth factor | Risk factors | Tumors | Cancer | Index Medicus
Journal Article